

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)



(10) International Publication Number
WO 2020/165087 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 47/26* (2006.01)
A61K 47/10 (2017.01) *A61K 47/60* (2017.01)
A61K 47/12 (2006.01) *A61P 5/18* (2006.01)
A61K 47/20 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2020/053316

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

10 February 2020 (10.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19156485.5 11 February 2019 (11.02.2019) EP
19168857.1 12 April 2019 (12.04.2019) EP

(71) Applicant: ASCENDIS PHARMA BONE DISEASES A/
S [DK/DK]; Tuborg Boulevard 5, 2900 Hellerup (DK).

(72) Inventors: SKANDS, Anja R.H.; c/o Ascendis Pharma
A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). CLEE-
MANN, Felix; c/o Ascendis Pharma GmbH, Im Neuen-
heimer Feld 584, 69120 Heidelberg (DE). SØRENSEN,
Michael Duelund; c/o Ascendis Pharma A/S, Tuborg
Boulevard 12, 2900 Hellerup (DK). BARON, Julia; c/o As-
cendis Pharma GmbH, Im Neuenheimer Feld 584, 69120
Heidelberg (DE). HOFFMANN, Eric; c/o Ascendis Phar-
ma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg
(DE). SPROGØE, Kennett; c/o Ascendis Pharma A/S,
Tuborg Boulevard 12, 2900 Hellerup (DK).

(74) Agent: BÜCHEL, Edwin; Patentanwälte Isenbruck Bösl
Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163
Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES

(57) Abstract: A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier moiety.



WO 2020/165087 A1